title: 4-Diazinyl- and 4-pyridinylimidazoles: potent angiotensin II antagonists. A study of their activity and computational characterization.
abstract: A series of N-[biphenylyl(tetrazolyl)methyl]-2-butylimidazoles containing variously substituted diazine or pyridine moieties either as their free bases or N-oxide derivatives attached to the 4-position of the imidazole ring was synthesized and tested for interaction with the AT1 receptors of rat adrenal cortex membranes (receptor binding assay). Some compounds were then chosen for further evaluation in vivo in the A II-induced pressor response in conscious normotensive rats. The most potent in the AT1 binding assay were found to be compounds in which the diazine or pyridine ring nitrogen is adjacent to the point of attachment between the two heteroaromatic rings such as 2-butyl-4-(3,6-dimethylpyrazin-2-yl)-1-[[2'-(1H-tetrazol-5-y l)-biphenyl-4- yl]methyl]-1H-imidazole (3b) or 2-butyl-4-[5-(methoxycarbonyl)pyrid-2-yl]-1-[[2'-(1H-tetrazol++ +-5- yl)biphenyl-4-yl]methyl]-1H-imidazole (6c). The binding affinities and oral activities of the pyridine N-oxide imidazoles in which a stabilizing group ortho to the pyridine ring nitrogen is present were markedly improved as in 2-butyl-4-[(3-methoxycarbonyl)-6-methyl-N-oxopyridin-2-yl]-1-[[2'- (1H- tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole 31b. Molecular modeling studies were carried out to determine the molecular electrostatic potential values of related model systems and to correlate their receptor interaction energies with the observed activities of our compounds.
authors.affiliation: Department of Medicinal Chemistry, Laboratori Guidotti S.p.A., Pisa, Italy.
authors.forename: N J
authors.initials: NJ
authors.lastname: Harmat
authors.forename: R
authors.initials: R
authors.lastname: Giorgi
authors.forename: F
authors.initials: F
authors.lastname: Bonaccorsi
authors.forename: G
authors.initials: G
authors.lastname: Cerbai
authors.forename: S M
authors.initials: SM
authors.lastname: Colombani
authors.forename: A R
authors.initials: AR
authors.lastname: Renzetti
authors.forename: R
authors.initials: R
authors.lastname: Cirillo
authors.forename: A
authors.initials: A
authors.lastname: Subissi
authors.forename: G
authors.initials: G
authors.lastname: Alagona
authors.forename: C
authors.initials: C
authors.lastname: Ghio
mesh_terms: D000284:Administration, Oral; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D001665:Binding Sites; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D007093:Imidazoles / Q000138:chemical synthesis* / Q000378:metabolism / Q000494:pharmacology*; D007700:Kinetics; D008297:Male; D051381:Rats; D017207:Rats, Sprague-Dawley; D013329:Structure-Activity Relationship
chemical_list: D057911:Angiotensin Receptor Antagonists; D007093:Imidazoles